Germany based pharmaceuticals company, Evotec AG, announced Wednesday that it will be buying the American company Renovis Inc. The deal, worth $151.8M USD will increase Evotec's research ability into treatments for inflammatory illnesses.
With an insomnia drug ready 
to begin human clinical trials and 5 other compounds expected to be in clinical trials the new combined Evotec expects to apply for NASDAQ listing.
"By combining Evotec's drug discovery and development know-how with Renovis' medicinal chemistry and target validation expertise, we expect to form a global biopharmaceutical company with world-class discovery capabilities," said Evotec Chief Executive Jorn Aldag.
If you want to read more details on the new Evotec aquisition check out this press release.
Comment Preview